Christian Gytz Ammitzbøll

Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial

Kim Hørslev‐Petersen, Merete Lund Hetland, Peter Junker et al. · Annals of the Rheumatic Diseases · 2013 · 124 citations · Full text

Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis

Christian Gytz Ammitzbøll, Lars Erik Bartels, J.B. Andersen et al. · ACR Open Rheumatology · 2021 · 85 citations · Full text

Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis

Lars Erik Bartels, Christian Gytz Ammitzbøll, J.B. Andersen et al. · Rheumatology International · 2021 · 72 citations · Full text

Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis

S. B. Krintel, Christian Dehlendorff, Merete Lund Hetland et al. · The Pharmacogenomics Journal · 2015 · 67 citations

Inflammation, Rheumatology, Double-blind Placebo-controlled Study +11

A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial

Mette Axelsen, Iris Eshed, Kim Hørslev‐Petersen et al. · Annals of the Rheumatic Diseases · 2014 · 63 citations · Full text